95 results on '"Sharma, M."'
Search Results
2. 257MO Integrating AI and ML with lung cancer diagnostics: A step ahead
3. 395P Molecular landscape of Indian NSCLC: Is NGS the answer?
4. 121P Treatment patterns and outcomes of recurrent/metastatic esophageal cancer: Real-world data
5. 269P MET alterations in EGFR mutated NSCLC: A lesser known evil
6. 263MO Variant allele frequency and copy number gain in EGFR mutated lung cancer: A menace or a boon?
7. 15P KRAS mutation in metastatic non-small cell lung carcinoma (NSCLC): The Indian subcontinent experience from a tertiary cancer center
8. 1509P Efficacy and safety of vimseltinib in tenosynovial giant cell tumour (TGCT): Phase II expansion
9. 475P Safety and efficacy of vimseltinib in tenosynovial giant cell tumour (TGCT): Long-term phase I update
10. 160P LungMetrics India: Molecular epidemiology and testing patterns in 4,773 non squamous NSCLC patients
11. 159P ReWARD study - Real-world ALK-resistance data: A single center experience
12. 518MO Tolerability and preliminary clinical activity of SY-5609, a highly potent and selective oral CDK7 inhibitor, in patients with advanced solid tumors
13. 1821P Safety and preliminary efficacy of vimseltinib in tenosynovial giant cell tumor (TGCT)
14. P-137 Phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations
15. 418P All EGFR mutations are (not) created equal: Focus on uncommon EGFR mutations
16. 330P COVID and cancer: Choosing between hammer and anvil
17. 1019O Phase I studies of Sym021, an anti-PD-1 antibody, alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
18. 1020O A phase I, first-in-human, open-label, dose escalation study of MGD019, an investigational bispecific PD-1 x CTLA-4 DART® molecule in patients with advanced solid tumours
19. NGS in advanced NSCLC in a developing country: Ready for prime time?
20. Correlation of circulating tumour cells with PET-CT in metastatic breast cancer
21. Role of ADC values in assessing response after chemoradiotherapy in cervix cancer and in identifying residual disease
22. Correlation of MRI derived parameters and SUV uptake obtained from FDG- PET-CT with human papillomavirus status in oropharyngeal squamous cell carcinomas
23. PD-L1 expression in ALK rearranged NSCLC: All questions answered?
24. 1448O Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) + lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)
25. 44P Pathological complete response to neoadjuvant chemotherapy and outcomes in Her-2 negative locally advanced breast cancer.
26. P-21 Molecular subtypes (profile) of colorectal cancer and their correlation with clinical and pathological profile in a tertiary care centre in India
27. Role of maintenance gemcitabine in advanced and metastatic carcinoma gall bladder
28. EGFR & PD L1: An (im)perfect union
29. Retrospective evaluation of PD-L1 expression in tumor tissue of patients with lung carcinoma and correlation with clinical and demographical data from a tertiary care institute of northern India
30. Safety and antitumor activity of pembrolizumab in patients with advanced microsatellite instability–high (MSI-H) colorectal cancer: KEYNOTE-164
31. Primary gastric diffuse large B cell lymphoma: A single center experience from developing country
32. QTWiST analysis to compare the benefit of maintenance Erlotinib versus pemetrexed patients with EGFR non mutated NSCLC
33. Discovery of novel 2beta-hydroxybetulinic acid 3beta-oliate via NF-κB pathway in diethylnitrosamine induced hepatocellular carcinoma in rats
34. Bone health in cancer survivors
35. Phase 2, multicenter, single-arm, open label study evaluating the combination of daratumumab + cyclophosphamide, bortezomib and dexamethasone (Dara-CyBorD) in previously untreated and relapsed patients (pts) with multiple myeloma (MM)
36. Phase 2 randomized study of daratumumab (dara), lenalidomide (R), bortezomib (V), and dexamethasone (d; Dara-RVd) vs. RVd in patients (pts) with newly diagnosed multiple myeloma (MM) eligible for high-dose therapy (HDT) and autologous stem cell transplantation (ASCT)
37. 505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
38. 377P - NGS in advanced NSCLC in a developing country: Ready for prime time?
39. 247P - Role of ADC values in assessing response after chemoradiotherapy in cervix cancer and in identifying residual disease
40. 44P - Correlation of circulating tumour cells with PET-CT in metastatic breast cancer
41. 117P - Correlation of MRI derived parameters and SUV uptake obtained from FDG- PET-CT with human papillomavirus status in oropharyngeal squamous cell carcinomas
42. 469P Clinical outcome study of crizotinib in IHC proven EML4-ALK fusion gene among Indian patients with adenocarcinoma lung
43. 119P Efficacy and safety profile of eribulin mesylate in advanced breast cancer: Single-centre experience from India
44. A phase 1 study of PF-06647020, an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients with advanced solid tumors including platinum resistant ovarian cancer (OVCA)
45. Everolimus use in breast cancer patients: a population-based study
46. 498P - Retrospective evaluation of PD-L1 expression in tumor tissue of patients with lung carcinoma and correlation with clinical and demographical data from a tertiary care institute of northern India
47. Angiogenic factors and laminin expression in cervical cancer: correlation with treatment response
48. Role of functional determinants of Th17 & Treg cells in immune evasion of urothelial carcinoma of bladder
49. P-122 - Primary gastric diffuse large B cell lymphoma: A single center experience from developing country
50. O-021 - Safety and antitumor activity of pembrolizumab in patients with advanced microsatellite instability–high (MSI-H) colorectal cancer: KEYNOTE-164
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.